Jazz Pharmaceuticals

"I can't die, I'm busy." This powerful phrase defined Jace's approach to life after he was diagnosed with diffuse midline #glioma (DMG) – a rare and aggressive brain tumor. Instead of focusing on limitations, he channeled his energy into making an impact by connecting people, encouraging those around him and advocating for continued progress in childhood cancer care.      Inspired by her son's impact, Lisa and her family continue to build upon his legacy to help expand research, advocacy and treatment options for other families facing rare brain cancers. See their story in honor of #BrainCancerAwarenessMonth: https://bit.ly/4nygGOp

#TuberousSclerosisComplex (TSC) is a rare genetic disorder that causes non-cancerous tumors to develop in multiple organs across the body – including the brain. The neurological changes driven by TSC can have a significant impact on daily life including developmental delays and cognitive impairment, as well as neuro-psychiatric challenges. Despite this, its highly variable presentation means diagnosis is often delayed – and in some cases TSC remains unrecognized. On #TSCGlobalDay and beyond, we are committed to raising awareness of TSC and advancing meaningful innovation to help address unmet needs for people living with this complex condition.

Neuro-oncology is an important area of research and development at Jazz, and one where we believe bold science can make the most difference for patients and their families.     From rare pediatric brain tumors like H3 K27M-mutant diffuse midline glioma (DMG) to other aggressive central nervous system cancers, we’re committed to going where the science leads and where patient need is greatest.    This #BrainTumorAwarenessMonth, we’re joining #GrayMay to reaffirm our dedication to the patients, caregivers and communities who inspire this work every day. Learn more about our work in rare brain cancers: https://bit.ly/432AUq2   #BTAM #BrainCancerAwarenessMonth 

We’re honored to be recognized for the third consecutive year by the Association of Strategic Alliance Professionals, winning the 2025 ASAP Alliance Excellence Award for Innovative Collaboration. Congratulations to Katherine Kendrick, CSAP and our alliance management team who accepted the award at the ASAP Global Summit this week. This recognition reflects an innovative and rigorous process of alliance partner financial health assessment designed to protect strategic alliance value and drive effective corporate and alliance decision making. Our alliance management team builds and sustains high-performing partnerships with the joint goal of supporting patients and their families. Learn more about the award: https://lnkd.in/e8tWhnKK

Many patients with diffuse midline #glioma (DMG), a rare and aggressive brain tumor, face a difficult reality: delayed diagnoses and limited access to the specialized care they need.     In recognition of #BrainCancerAwarenessMonth, hear from Amanda Saratsis, MD, Senior Director, Global Medical Affairs Oncology at Jazz as she shares insights on the need for early molecular diagnostic testing in patients with rare brain cancers like DMG: https://bit.ly/42Q0wGG

#News for U.S. media and investors: Jazz announces first quarter 2026 financial results $JAZZ: https://bit.ly/49v7VyN

Congratulations to our 2026 Healthcare Businesswomen’s Association (HBA) Luminary, Kristin Bhavnani and Rising Star, Eloho Ojabunor and to Rick Winningham, our lead independent director of the Jazz Pharmaceuticals Board of Directors, as the HBA Honorable Mentor of the Year for 2026. Their leadership, impact, and commitment to advancing women across healthcare were recognized last week during the HBA Global Ascension Leadership Experience. We’re proud to see their achievements acknowledged among such an inspiring community of industry leaders. A special congratulations to all members of the 2026 HBA Rising Stars and Luminaries class—an incredible group shaping the future of healthcare. #AscendWithHBA #HBAImpact

#News for U.S. media and investors: We’re excited to share that the U.S. FDA has accepted and granted Priority Review for the supplemental Biologic License Application (sBLA) for our potential treatment for HER2+ unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). Learn more: https://bit.ly/4sYvF5s   Backed by Phase 3 data, this milestone highlights an important step forward in our ongoing efforts to help redefine care for people living with this aggressive, difficult-to-treat cancer. 

We were pleased to host a fireside chat featuring Renee Gala and Sheila Gujrathi, MD.  Our President & CEO Renee Gala recently sat down with biotech leader, board chair and author, Sheila Gujrathi, M.D., for a thoughtful conversation on leadership, purpose, and building organizations that aspire to make a meaningful difference for patients. They explored leading with clarity and authenticity, navigating moments of change and growth, unlocking high performance, and the importance of values-driven leadership in biopharma. We’re grateful to Dr. Gujrathi for sharing her insights and perspective, and to Renee for her continued leadership and commitment to fostering open, meaningful dialogue across our industry.

#News for U.S. media and investors: At #ASCO26, we’ll be presenting data that spotlights meaningful advancements across our oncology portfolio, including gastroesophageal adenocarcinoma and extensive-stage small cell lung cancer. Learn more here: https://bit.ly/4mT4Xtx   Our presence at ASCO underscores our continued commitment to advancing innovative treatment approaches for patients facing some of the most difficult-to-treat cancers.